Strata Critical Medical, Inc. (SRTA)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
$5.22-1.69%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Strata is growing revenue toward $260-275M in 2026. Free cash flow is expected between $15M and $22M. The company recently beat earnings and completed acquisitions to expand. Profitability is improving but still fragile.
Strata remains unprofitable with negative EPS expected in 2026. Earnings misses and a recent sharp selloff show risk. Free cash flow yield is negative and margin targets are uncertain.
The price is about 41% below our fair value near $9. Analysts expect 21% revenue growth. Our view aligns with this but risks remain given unprofitability and recent volatility.
Breaks if: Adjusted EBITDA falls below $29 million in FY26
Breaks if: Free cash flow falls below $15 million in FY26
Breaks if: Revenue falls below $260 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the healthcare sector. While SRTA is currently loss-making, management is focused on achieving revenue and EBITDA growth, indicating a potential recovery over the multi-year horizon.
The market appears to have priced in a low expectations gap, suggesting that investors are not overly optimistic about SRTA's near-term performance. Valuation is considered cheap compared to peers, which may reflect the current challenges the company faces.
Management is on track to meet its revenue and EBITDA guidance for 2026, which could support a gradual improvement in fundamentals. However, there is a near-term risk of missing estimates, as indicated by the company's recent erratic earnings surprises.
The future performance of SRTA hinges on management's ability to meet guidance and the overall health of the healthcare sector. Key factors include the performance of sector bellwethers and the potential impact of economic conditions on demand for healthcare services.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has negatively impacted the outlook. This suggests that the company's performance may not meet previous expectations.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management aims to achieve a revenue range of $260-275 million for the fiscal year 2026.
In the next 1 to 3 years, SRTA's trajectory will depend on successful execution of its operational goals and broader market conditions. Not investment advice.